SCHEMBL1622985

SCHEMBL1622985

Cc1ccc2c(N3CCC(NC(=O)c4cccnc4)C3)nc(-c3ccccc3O)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.47
PIK3CA P42336 1/20 0.42
KDM5A P29375 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMAD3 P84022 1/20 0.41
ACKR3 P25106 2/20 0.41
AKT1 P31749 1/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1622981 1.00 CHEK2 (0.47) CHEK2PIK3CAKDM5AMEN1KMT2A
SCHEMBL1622826 0.91 CHEK2 (0.49) CHEK2KDM5AMEN1KMT2ASMAD3
SCHEMBL1622822 0.91 CHEK2 (0.49) CHEK2KDM5AMEN1KMT2ASMAD3
SCHEMBL1622377 0.88 CHEK2 (0.49) CHEK2PIK3CAKDM5AMEN1KMT2A
SCHEMBL1622381 0.88 CHEK2 (0.49) CHEK2PIK3CAKDM5AMEN1KMT2A
SCHEMBL183925 0.87 CHEK2 (0.56) CHEK2MEN1KMT2ASMAD3AKT1
SCHEMBL1624858 0.87 CHEK2 (0.56) CHEK2MEN1KMT2ASMAD3AKT1
SCHEMBL183924 0.87 CHEK2 (0.56) CHEK2MEN1KMT2ASMAD3AKT1
SCHEMBL1622674 0.87 CHEK2 (0.47) CHEK2KDM5AMEN1KMT2ASMAD3
SCHEMBL1622668 0.87 CHEK2 (0.47) CHEK2KDM5AMEN1KMT2ASMAD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885PIK3CA 1173/4885KDM5A 2146/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885PIK3CA 1173/4885KDM5A 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.